ISIS-APOCIIIRx: Phase II started

Isis began a 3-month, double-blind, placebo-controlled, Canadian Phase II trial to evaluate subcutaneous ISIS-APOCIIIRx in about 100 patients with triglyceride levels of >=500 mg/dL. ...